Dutch biotehnology firm Pharming NV has reported positive safety and efficacy data from a European randomized placebo-controlled Phase III clinical trial of its recombinant human C1 inhibitor, Rhucin, for the acute treatment of hereditary angioedema. According to the firm, the positive results from an interim analysis of the evaluation follow earlier studies showing the strong positive effect of Rhucin coupled with an excellent safety profile.
In the Phase III double-blind, placebo-controlled, 28-patient study, participants on Rhucin reported the onset of relief at a median time of 60 minutes after administration compared to 8.5 hours for those who received placebo. The primary endpoint, time-to-beginning of symptom relief, achieved statistical significance (p=0.0009) as measured by the log-rank test. In addition, subjects on Rhucin reported minimal symptoms at a median time of 6.1 hours, which compares favorably with the 20.2 hours experienced by subjects in the placebo cohort.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze